%0 Journal Article
%A Fleischmann, Maximilian
%A Kristen, Alexander
%A Winkelmann, Ria
%A Burck, Iris
%A Weigert, Andreas
%A Issing, Christian
%A Diefenhardt, Markus
%A Martin, Daniel
%A Brandts, Christian
%A Rödel, Franz
%A Balermpas, Panagiotis
%A von der Grün, Jens
%A Thönissen, Philipp
%A Rödel, Claus
%A Ghanaati, Shahram
%T Neoadjuvant chemoradiation for patients with resectable locally advanced oral cavity squamous cell carcinoma: Results of the prospective INVERT clinical trial.
%J Oral oncology
%V 164
%@ 1368-8375
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2025-00643
%P 107252
%D 2025
%Z ISSN 1368-8375
%X The INVERT trial is a prospective, monocentric, proof-of-principle phase 2clinical trial evaluating the safety and efficacy of neoadjuvant chemoradiation (CRT) inpatients with resectable, locally advanced oral cavity squamous cell carcinoma (LAOCSCC).Eligible patients received intensity-modulated radiotherapy (IMRT) to primarytumor and nodal volumes (60/54/50 Gy in 30 fractions) with concomitant platinumbasedchemotherapy. Surgery was performed 6-8 weeks after CRT. Primary endpointwas the pathological complete response (pCR = ypT0N0) rate. Secondary endpointsincluded R0 resection rate, surgical complications, oncological outcomes, and qualityof life.Between 02/2012 and 09/2022, 28 UICC Stage (7th edition) IVA-IVB LAOCSCCpatients were enrolled; 92.1 
%K Chemoradiation (Other)
%K Chemoradiotherapy (Other)
%K Chemotherapy (Other)
%K IMRT (Other)
%K Multimodal (Other)
%K Neoadjuvant (Other)
%K Oral cavity squamous cell carcinoma (Other)
%K Surgery (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40147285
%R 10.1016/j.oraloncology.2025.107252
%U https://inrepo02.dkfz.de/record/300157